scholarly journals FOOD SAFETY MANAGEMENT IN LIGHT OF PANDEMIC COVID-19FOR MEDIUM CARE POSITIVE CASES UNIT(MCU)AT 57357CCHE

2021 ◽  
Vol 9 (02) ◽  
pp. 953-960
Author(s):  
Afaf A. Amin ◽  
◽  
Gulsen A. Saleh ◽  
Ahmed S. Khedr ◽  
◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Safety Management ◽  
The Other ◽  
World Health ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Tract Infections ◽  
The City

COVID-19 is a new strain of coronavirus to which humans have not got immunity. It originated in China and has quickly spread around the world.It is a disease caused by an infection by SARS-CoV-2 virus, first identified in the city of Wuhan, in Chinas Hubei province in December 2019. COVID-19 was previously known as 2019 Novel Coronavirus (2019-nCoV) respiratory disease before the World Health Organization (WHO) declared the official name as COVID-19 in February 2020. Like the other coronaviruses, the SARS-CoV-2 virus primarily causes respiratory tract infections, and the severity of the COVID-19 disease can range from mild to fatal.

scholarly journals Drugs used for the treatment of COVID-19: A Review

2021 ◽  
Vol 16 (1) ◽  
pp. 45-51
Author(s):  
MM Bodiuzzaman
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Tract ◽  
Respiratory Distress Syndrome ◽  
Respiratory Tract Infections ◽  
Distress Syndrome ◽  
Empirical Therapy ◽  
World Health ◽  
Health Organization ◽  
Tract Infections ◽  
The City

COVID-19 is primarily a respiratory disease caused by a newly discovered SARS-CoV-2 virus and identified in the city of Wuhan, China in December 2019. World Health Organization (WHO) has declared this disease as a pandemic, and warned other countries. Presently this has affected 221 countries, areas or territories worldwide, Spreading of this disease is very fast in USA, India, Brazil, and Russia than in the country of its origin China. Like other coronaviruses, this may develop respiratory tract infections in the patients range from mild to fatal illness like pneumonia and acute respiratory distress syndrome (ARDS). Bangladesh, a country of 170 million people, is not an exception regarding COVID-19; it has been reported 5,70,800 confirmed cases with 8690 documented deaths. Still now no effective drug, vaccine, or any procedure is available and experiments are underway. However, empirical therapy is being followed to manage and save the lives of the patients. There is a need for pharmacological alternatives to combat this deadly virus and its complications. Based on the previous experiences with similar coronavirus management and present preliminary data from uncontrolled studies, drugs like Chloroquine, Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir, and Favipiravir have been recommended by the researchers to manage COVID-19. This review had assessed the potential mechanisms, safety profile, availability and cost of these drugs. This review concludes that the drugs mentioned above are having different properties and act differently in combating the COVID-19 viruses. Faridpur Med. Coll. J. 2021;16(1):45-51

scholarly journals COVID-19 Diagnosis, Treatments and Prevention: A Review

2020 ◽  
pp. 17-34
Author(s):  
Soumik Chatterjee ◽  
Sabyasachi Chatterjee
Keyword(s):  
Immune System ◽  
Respiratory Tract ◽  
World Health Organization ◽  
Clinical Characteristics ◽  
Treatment Strategies ◽  
World Health ◽  
Upper Respiratory Tract ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

Novel Coronavirus are very harmful virus. This viruses have positive single stranded RNA genome and enveloped which is called nucleocapsid. The family of this virus is Coronaviridae. This virus originated from species of avian and mammalian. This virus effect on upper respiratory tract in humans. Many species of these novel coronaviruses (HCoVs) are named as HCoV-HKU1, HCoV-NL63. Predominant species of this virus is Middle East respiratory syndrome (MERS-CoV) across the world.  In both adults and childrens HCoV-HKU1 sp. is causes for chronic pulmonary disease and HCoV-NL63 species causes for upper and lower respiratory tract disease. Most recent species of this virus is MERS-CoV. This species caused for acute pneumonia and occasional renal failure. The new strain of novel Coronavirus is SARS-CoV-2. This strain causes for the Coronavirus Disease 2019 (COVID-19). This disease named by the World Health Organization. Now world fighting against COVID-19 and according to the recent statistics report of world about the COVID-19 cases approx 22.6M confirmed cases and 792K death cases appeared and recovered 14.5M. COVID-19 disease starts to spread from December 2019 from china. Covid-19 disease is emerged in Wuhan seafood market at Wuhan of South China and then rapidly spread throughout the world. The corona virus outbreak has been declared a public health emergency of International concern by World Health Organization (WHO). In this article we summarize the current clinical characteristics of coronavirus and diagnosis, treatments and prevention of COVID-19 disease. In this review article, we analyze data from various Research Reports like WHO guidelines and other articles. It is very important to the readers that new data of COVID-19 updating nearly every hour of day regarding clinical characteristics, diagnosis, treatment strategies, and outcomes COVID-19 disease. The degree of COVID-19 disease varying throughout the world. COVID-19 affected patient shows various symptoms like fever, cough, sore throat, breathlessness, fatigue, and malaise among others. The COVID-19 disease is being treated through general treatment like symptomatic treatment, by using antiviral drugs, oxygen therapy and by the immune system. There is no vaccine or therapeutic strategies for deal with this disease yet. In this critical situation preventive measures must be require.  A very important issue in preventing viral infection is hand hygiene. There are other entities that people can boosting the immune system and help in infection prevention.

scholarly journals IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY

2020 ◽  
pp. 1-4
Author(s):  
Naveen Kishoria ◽  
S.L Mathur ◽  
Veeram Parmar ◽  
Rimple Jeet Kaur ◽  
Harish Agarwal ◽  
...  
Keyword(s):  
Clinical Study ◽  
Standard Treatment ◽  
World Health ◽  
Unknown Etiology ◽  
Open Label ◽  
Randomized Clinical Study ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization ◽  
The City

A cluster of pneumonia cases of unknown etiology was reported from the city of Wuhan, in the Hubei province of China, in December 2019. A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of the disease which was subsequently termed as the coronavirus disease (COVID-19) by the World Health Organization (WHO). SARS-CoV-2 mainly affects the lower res-piratory tract and manifests as pneumonia in humans.

scholarly journals An Overview of Antivirals for Treating Lower Respiratory Tract Infections

2021 ◽  
Vol 66 (1) ◽  
Author(s):  
Alicia Elvira Cruz Jiménez ◽  
Liliana Quintanar Vera ◽  
J. Armando Lujan-Montelongo
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
World Health ◽  
High Morbidity ◽  
Lower Respiratory Tract Infections ◽  
Viral Pathogens ◽  
El Sistema ◽  
Health Organization ◽  
Tract Infections

Abstract. Covid-19 has resulted in a worldwide epidemic (pandemic) with high morbidity and mortality, which has generated efforts in various areas of research looking for safe and effective treatments to combat the virus that generates this disease: SARS-CoV-2. However, several viruses have been emerged/adapted in the last few decades, also affecting the respiratory system. According to the world health organization (WHO), lower respiratory tract infections (LRTIs) are one of the leading causes of death worldwide, and viruses are playing important roles as the cause of these infections. In contrast to the vast repertoire of antibiotics that exist to treat bacteria-caused LRTIs, there are a very few antivirals approved for the treatment of virus-caused LRTIs, whose approach consists mainly of drug reuse. This minireview deals on the main viral pathogens that cause LRTIs and some of the most relevant antivirals to counter them (available drugs and molecules in research/clinical trials), with concise comments of their mechanism of action.   Resumen. Covid-19 ha resultado en una epidemia mundial (pandemia) con alta morbilidad y mortalidad, lo que ha generado esfuerzos en diversas áreas de investigación en la búsqueda de tratamientos seguros y eficaces para combatir el virus que genera esta enfermedad: el SARS-CoV-2. Sin embargo, un número de virus han surgido o se han adaptado en las últimas décadas, que también afectan el sistema respiratorio. Según la Organización Mundial de la Salud (OMS), las infecciones en vías respiratorias inferiores (LRTIs, por sus siglas en inglés) son una de las principales causas de muerte a nivel mundial, siendo los virus de los principales patógenos causantes de estas infecciones. En contraste con el repertorio amplio de antibióticos que existen para tratar LRTIs causadas por bacterias, existen muy pocos antivirales aprobados para su tratamiento, cuyo enfoque consiste principalmente en la reutilización de fármacos. Este ensayo consiste en una breve revisión de los principales agentes virales que causan LRTIs y de los antivirales más relevantes para combatir los virus que las causan (tanto fármacos disponibles como moléculas en fases de investigación o clínicas), con comentarios concisos sobre su mecanismo de acción.

Pharmacological Efficacy and Safety of Glycyrrhiza glabra in the treatment of respiratory tract infections

2021 ◽  
Vol 21 ◽  
Author(s):  
Shadma Wahab ◽  
Irfan Ahmad ◽  
Safia Irfan ◽  
Ayesha Siddiqua ◽  
Shazia Usmani ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Clinical Medicine ◽  
Respiratory Infections ◽  
Glycyrrhiza Glabra ◽  
World Health ◽  
Chronic Obstructive ◽  
Virus Growth ◽  
The World ◽  
Tract Infections

: Respiratory tract infections are underestimated because they are mild and disabling, but in clinical medicine, these are the most prevalent problems. According to the World Health Organization third-most comprehensive cause of death in the world till 2030 would be chronic obstructive pulmonary disease (COPD). Dominating viruses of respiratory infections are influenza, respiratory syncytial virus, rhinoviruses, and human coronaviruses. Antibiotics are mostly used to treat bacterial infections, and they do not effectively manage viral infections like sinusitis, sore throats, bronchitis, influenza, and common respiratory infections. Presently no medication is available only symptomatic interventions is an option in our hand. However, a lot of research is going on the vaccine and drugs-based approaches against respiratory viruses worldwide. Traditional medicines are getting the attraction to treat many diseases. It is vital to screen the medicinal plants to find the potential of new compounds for treatment against antiviral and antimicrobial activities. Glycyrrhiza glabra L. (Licorice) pharmacological actions modulate the immune system, inhibit virus growth, produce anti-inflammatory activity, and inactivate viruses. This comprehensive review mainly focuses on the role of licorice in managing respiratory infections caused by viruses and bacteria, including complications associated with its excess intake. There has been limited human research’s exhibited licorice effectiveness in respiratory infections; therefore, there is a need for uncompromising and long-term research. This paper will be a valuable reference for biologists and physicians looking for a medication for respiratory infections. Glycyrrhiza glabra could open the door to novel agents in drug discovery and development.

The outbreak of Novel Coronavirus a New Type of Threat in 2020: Genesis, Detection, Treatment, and Management

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Dinesh Mohan S ◽  
Santhosha D ◽  
Gupta VRM ◽  
Mrunalini S
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Primary Source ◽  
World Health ◽  
London School ◽  
Live Animal ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Approved Drugs

Background: COVID-19 is a new, health-threatening infectious disease in the world in 2020, caused novel coronavirus SARS-CoV-2. As of July 13, 2020, 4,881,579 active cases of COVID-19 have been diagnosed and 571,080 deaths globally. In India, 301,850 active cases and 23,187 deaths have been reported. To date, there is no effective treatment made available against the deadly virus SARS-CoV-2. The drug manufacturers, institutional laboratories, and other organizations start developing vaccines to combat the COVID-19 infection. Methods: Science Direct, Elsevier, Pub med, Scopus, and Nature databases were referred to know the current scenario of disease. Moreover, the recent data has also been obtained from the World Health Organization (WHO), Centre of Disease Control (CDCs), case studies, newspaper, and worldometer reports. Vaccine Centre at the London School of Hygiene & Tropical Medicine, Clinicaltrials.gov, US National Library of Medicine, has also been accessed to get the latest information about ongoing clinical trials. Result: The primary source of the SARS-CoV-2 outbreak is connected to the Hunan seafood and live animal market in Wuhan city, Hubei Province, China. Like; SARS-CoV, and MERS-CoV, SARS-CoV-2 is also a zoonotic virus affecting the lower respiratory tract in humans. The pathogenesis of COVID-19 involves attachment of its Spike (S) protein to the angiotensin-converting enzyme 2 (ACE2) receptor in the lower respiratory tract in humans. The most common symptoms of COVID-19 are fever, cough, sore throat, fatigue, headache, myalgia, septic shock, and breathlessness. Few patients with COVID-19 infection experience diarrhea, vomiting, and abdominal pain. Currently, FDA approved drugs being used to treat COVID-19. Conclusion: This review article presents the importance of traditional Indian herbs recommended by AYUSH as precautionary and curative measures of COVID-19 until vaccines and drugs are made available. Moreover, this article discussed the origin, symptoms, mode of transmission, management, and diagnostics techniques for the detection of the SARS-CoV-2 virus.

scholarly journals Do pollution and climate influence respiratory tract infections in children?

2014 ◽  
Vol 60 (3) ◽  
pp. 276-282 ◽  
Author(s):  
Saulo Duarte Passos ◽  
Rosa Estela Gazeta ◽  
Ana Paula Felgueiras ◽  
Patrícia Costa Beneli ◽  
Micheline de S. Z. S. Coelho
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Pediatric Population ◽  
Clinical Importance ◽  
Respiratory Viruses ◽  
World Health ◽  
Human Bocavirus ◽  
Syncytial Virus ◽  
Health Organization ◽  
Tract Infections

To review if pollution and climate changes can influence respiratory tract infections in children. Data source: articles published on the subject in PubMed, SciELO, Bireme, EBSCO and UpTodate were reviewed. The following inclusion criteria were considered: scientific papers between 2002 and 2012, study design, the pediatric population, reference documents such as the CETESB and World Health Organization Summary of the data: We analyzed research that correlated respiratory viruses and climate and/or pollution changes. Respiratory syncytial virus has been the virus related most to changes in climate and humidity. Other "old and new" respiratory viruses such as Human Bocavirus, Metapneumovirus, Parechovirus and Parainfuenza would need to be investigated owing to their clinical importance. Although much has been studied with regard to the relationship between climate change and public health, specific studies about its influence on children's health remain scarce.

scholarly journals A Systematic Review on Coronavirus Disease 2019 (COVID-19)

2020 ◽  
Author(s):  
Hira Karim ◽  
Muhammad Shahzeb Khan
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Transmission Dynamics ◽  
World Health ◽  
Clinical Aspects ◽  
Viral Strain ◽  
Health Organization ◽  
Tract Infections

Emerging and reemerging pathogens is a global challenge for public health. Recently, a novel coronavirus disease emerged in Wuhan, Hubei province of China, in December 2019. It is named COVID-19 by World Health Organization (WHO). It is known to be caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that affects the lower respiratory tract and manifests as pneumonia in humans. Coronaviruses (CoVs) are structurally more complicated as compared to other RNA viruses. This viral epidemic has led to the deaths of many, including the elderly or those with chronic disease or compromised immunity. Viruses cause infection and diseases in humans of varying degrees, upper respiratory tract infections (URTIs) cause common cold while lower respiratory tract infections induce pneumonia, bronchitis, and even severe acute respiratory syndrome (SARS). The costs of COVID-19 are not limited. It equally affects all the medical, sociological, psychological, and economic aspects globally. This is regarded as the third deadly outbreak in the last two decades after Severe Acute Respiratory Syndrome SARS (2002–2003) and Middle East Respiratory Syndrome MERS (2012). Based on the sequence homology of SARS-CoV-2, different animal sources including bats, snakes, and pangolins have been reported as potential carriers of this viral strain. Real-time RT-PCR represents the primary method for the diagnosis of new emerging viral strain SARS-CoV-2. The transmission dynamics suggest that SARS-CoV-2 is transmitted from person-to-person through direct contact or coughing, sneezing, and by respiratory droplets. Several anti-viral treatments including lopinavir/ritonavir, remdesivir, chloroquine phosphate, and abidor are also suggested with different recommendations and prescriptions. Protective and preventive strategies as suggested by various health organization i.e. WHO and US Center for Disease Control and Prevention (CDC) must be adopted by everyone. This review covers the important aspects of novel COVID-19 including characteristics, virology, symptoms, diagnostics, clinical aspects, transmission dynamics, and protective measures of COVID-19.

Current updates on COVID-19 - A review

2020 ◽  
Vol 10 (1) ◽  
pp. 1-8
Author(s):  
Ghotekar D S ◽  
Vishal N Kushare ◽  
Sagar V Ghotekar
Keyword(s):  
World Health Organization ◽  
Common Cold ◽  
Respiratory Diseases ◽  
Gastrointestinal Diseases ◽  
Hubei Province ◽  
World Health ◽  
The World ◽  
The Common ◽  
Novel Coronavirus ◽  
Health Organization

Coronaviruses are a family of viruses that cause illness such as respiratory diseases or gastrointestinal diseases. Respiratory diseases can range from the common cold to more severe diseases. A novel coronavirus outbreak was first documented in Wuhan, Hubei Province, China in December 2019. The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) a pandemic. A global coordinated effort is needed to stop the further spread of the virus. A novel coronavirus (nCoV) is a new strain that has not been identified in humans previously. Once scientists determine exactly what coronavirus it is, they give it a name (as in the case of COVID-19, the virus causing it is SARS-CoV-2).

Sign in / Sign up

Export Citation Format

Share Document